TR199902508T2 - HIV protease inhibitors. - Google Patents

HIV protease inhibitors.

Info

Publication number
TR199902508T2
TR199902508T2 TR1999/02508T TR9902508T TR199902508T2 TR 199902508 T2 TR199902508 T2 TR 199902508T2 TR 1999/02508 T TR1999/02508 T TR 1999/02508T TR 9902508 T TR9902508 T TR 9902508T TR 199902508 T2 TR199902508 T2 TR 199902508T2
Authority
TR
Turkey
Prior art keywords
hiv protease
hiv
protease inhibitors
compounds
virus
Prior art date
Application number
TR1999/02508T
Other languages
Turkish (tr)
Inventor
F. Albizati Kim
Reich Siegfried
D. Varney Michael
E. Zhang Kanyin
Kobayshi Takuo
Original Assignee
Agouron Pharmaceuticals, Inc.
Japan Tobacco Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals, Inc., Japan Tobacco Inc. filed Critical Agouron Pharmaceuticals, Inc.
Publication of TR199902508T2 publication Critical patent/TR199902508T2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/36Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Kimyasal sentez yolu ile elde edilebilen HIV proteaz inhibitörleri, HIV proteazin biyolojik aktivitesini inhibe ederek veya bloke ederek, HIV virüsünün replikasyonunun son bulmasina neden olurlar. Bu bilesikler yani sira, aktif bilesen olarak bu bilesikleri ve ihtiyari olarak baska anti virütik maddeler ihtiva eden farmasötik terkipler, AIDS'e neden oldugu bilinen HIV virüsü ile enfekte olmus hastalari veya konaklari tedavi etmek için yararlidirlar.HIV protease inhibitors, which can be obtained by chemical synthesis, inhibit or block the biological activity of HIV protease, resulting in the replication of the HIV virus. In addition to these compounds, pharmaceutical compositions that contain these compounds as an active ingredient and optionally other anti-virus agents are useful for treating HIV-infected patients or hosts known to cause AIDS.

TR1999/02508T 1997-03-13 1998-03-12 HIV protease inhibitors. TR199902508T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81595197A 1997-03-13 1997-03-13

Publications (1)

Publication Number Publication Date
TR199902508T2 true TR199902508T2 (en) 2000-02-21

Family

ID=25219265

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02508T TR199902508T2 (en) 1997-03-13 1998-03-12 HIV protease inhibitors.

Country Status (35)

Country Link
EP (1) EP0970055A2 (en)
JP (1) JP2001516350A (en)
KR (1) KR100511089B1 (en)
CN (1) CN1179948C (en)
AP (1) AP1358A (en)
AR (1) AR012556A1 (en)
AU (1) AU743078B2 (en)
BG (1) BG63540B1 (en)
BR (1) BR9808867A (en)
CA (1) CA2284163A1 (en)
CO (1) CO4940496A1 (en)
CZ (1) CZ296647B6 (en)
EA (1) EA002378B1 (en)
EE (1) EE04114B1 (en)
GE (1) GEP20022764B (en)
HR (1) HRP980112A2 (en)
HU (1) HUP0001380A3 (en)
IL (2) IL131870A0 (en)
IS (1) IS5176A (en)
MX (1) MXPA99008395A (en)
MY (1) MY117535A (en)
NO (1) NO315555B1 (en)
NZ (1) NZ337706A (en)
OA (1) OA11196A (en)
PA (1) PA8448801A1 (en)
PE (1) PE58799A1 (en)
PL (1) PL192786B1 (en)
SA (1) SA98181116B1 (en)
SK (1) SK283636B6 (en)
SV (1) SV1998000038A (en)
TR (1) TR199902508T2 (en)
TW (1) TW200517112A (en)
UA (1) UA57772C2 (en)
WO (1) WO1998040357A2 (en)
ZA (1) ZA982047B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors

Also Published As

Publication number Publication date
AP9901648A0 (en) 1999-09-30
NZ337706A (en) 2001-04-27
KR100511089B1 (en) 2005-08-31
SK283636B6 (en) 2003-11-04
WO1998040357A2 (en) 1998-09-17
EA002378B1 (en) 2002-04-25
AP1358A (en) 2004-12-03
IL131870A (en) 2006-04-10
PA8448801A1 (en) 2000-05-24
MXPA99008395A (en) 2003-08-12
SV1998000038A (en) 1999-02-15
OA11196A (en) 2003-05-21
AU743078B2 (en) 2002-01-17
CZ319199A3 (en) 2000-06-14
CN1253548A (en) 2000-05-17
SK122299A3 (en) 2000-05-16
NO994415L (en) 1999-11-10
BG103727A (en) 2000-04-28
BG63540B1 (en) 2002-04-30
PL335672A1 (en) 2000-05-08
CZ296647B6 (en) 2006-05-17
AU6457598A (en) 1998-09-29
CN1179948C (en) 2004-12-15
EE04114B1 (en) 2003-08-15
AR012556A1 (en) 2000-11-08
KR20000076236A (en) 2000-12-26
NO315555B1 (en) 2003-09-22
ZA982047B (en) 1998-09-28
TW200517112A (en) 2005-06-01
HUP0001380A3 (en) 2001-12-28
IL131870A0 (en) 2001-03-19
NO994415D0 (en) 1999-09-10
UA57772C2 (en) 2003-07-15
CA2284163A1 (en) 1998-09-17
BR9808867A (en) 2000-07-11
GEP20022764B (en) 2002-08-26
WO1998040357A3 (en) 1998-11-26
CO4940496A1 (en) 2000-07-24
PE58799A1 (en) 1999-07-12
SA98181116B1 (en) 2006-10-04
MY117535A (en) 2004-07-31
PL192786B1 (en) 2006-12-29
EA199900823A1 (en) 2000-04-24
JP2001516350A (en) 2001-09-25
HRP980112A2 (en) 1998-12-31
EP0970055A2 (en) 2000-01-12
HUP0001380A2 (en) 2000-09-28
EE9900416A (en) 2000-04-17
IS5176A (en) 1999-09-10

Similar Documents

Publication Publication Date Title
MY138860A (en) Hiv protease inhibitors.
TR200401314T2 (en) Substituted oxazolidinones and their use
EA199901031A1 (en) Derivatives of benzimidazole
ID21526A (en) 4-HYDROXYQUINOLIN-3-CARBOXOXIDE AND HYDRAZIDE AS ANTI-VIRUS INGREDIENTS
DE69518840T2 (en) N- (3-AMINO-2-HYDROXYBUTYL) SULFONAMIDE DERIVATIVES AS HIV PROTEASE INHIBITORS
EA200400026A1 (en) HIV PROTEASE INHIBITORS, CONTAINING THEIR COMPOSITIONS, THEIR PHARMACEUTICAL APPLICATIONS AND SUBSTANCES FOR THEIR SYNTHESIS
BG102048A (en) Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors
DK0750618T3 (en) Oxazolidinone derivatives and pharmaceutical preparations containing them
ES2132383T3 (en) PROTEASE HIV INHIBITORS.
DE69909747D1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING PEG-ASPARAGINASE, FOR THE TREATMENT OF HIV INFECTIONS
ATE309803T1 (en) SPHINGOMYELINASE INHIBITORS AS ACTIVE INGREDIENTS WITH ANTIAPOPTOTIC AND ANTISEPTIC EFFECTS
TR200003797T2 (en) New preparations derived from alpha-D-xylose, their preparation methods and uses for treatment.
TR199902508T2 (en) HIV protease inhibitors.
EE9900188A (en) 1- (3-Aminoindazol-5-yl) -3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
IT1318424B1 (en) COMPOUNDS WITH ANTI-HIV ACTIVITY.
TR200102019T2 (en) The use of 3-isoxazolidinones and hydroxylamic acids in the treatment of infections.
DE69426574T2 (en) MACROCYCLIC DIFLUOROSTATON DERIVATIVES AS AN ANTIVIRAL AGENT
TH14264B (en) HIV protease inhibitors